Home / Companies / C4 Therapeutics, Inc. / 20 Jun 2024
C4 Therapeutics, Inc.: meeting of 20 Jun 2024
Votes reported on Form N-PX, item by item
123 Form N-PX filers reported votes at the C4 Therapeutics, Inc. meeting of 20 Jun 2024. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
3 nominees; 43.1% of reported votes for; 26 filers withheld from or voted against at least one nominee.
174 vote records from 36 filers. 18 of the 35 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
159 vote records from 123 filers. 72 of the 115 filers that marked the item either way voted against management. 8 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
58 vote records from 36 filers. 0 of the 35 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | Against * | For |
| BlackRock and iShares | For | Against * | For |
| Fidelity | For | Against * | For |
| Dimensional | Abstain or withhold * | Against * | For |
| State Street and SPDR | For | For | For |
| American Century | Abstain or withhold * | Against * | For |
| Franklin Templeton | For | Abstain or withhold * | For |
| Invesco | Abstain or withhold * | Against * | For |
| Equitable | Abstain or withhold * | Against * | For |
| Charles Schwab | For | For | For |
| ProShares and ProFunds | Abstain or withhold * | Against * | For |
| John Hancock and Manulife | Abstain or withhold * | Against * | For |
| Morgan Stanley, Eaton Vance and Calvert | No report | Against * | No report |
| Goldman Sachs | No report | Against * | No report |
| PGIM and Prudential | No report | For | No report |
| Jackson National funds | Abstain or withhold * | Against * | For |
| Northern Trust and FlexShares | No report | For | No report |
| SEI | For | For | For |
| T. Rowe Price | Abstain or withhold * | Against * | For |
| Nationwide | Abstain or withhold * | Against * | For |
| Guggenheim and Rydex | Abstain or withhold * | Against * | For |
| Columbia Threadneedle | No report | Against * | No report |
| BNY Mellon | No report | Against * | No report |
| MassMutual | Split or no vote | Split or no vote | Split or no vote |
| Harbor Funds | For | For | For |
| Janus Henderson | No report | Against * | No report |
| Natixis and Loomis Sayles | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the C4 Therapeutics, Inc. meeting?
123 Form N-PX filers reported votes at the meeting of 20 Jun 2024. On say-on-pay, 72 of 115 voted against management (62.6%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by C4 Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for C4 Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing C4 Therapeutics, Inc. with a meeting date within three days of 20 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.